Literature DB >> 34003325

Eculizumab, a real-life successful treatment for refractory cold agglutinin-mediated auto-immune hemolytic anemia secondary to lymphoproliferative disorders.

Laura Herbreteau1, Ronan Le Calloch2, Bertrand Arnaud3, Nicolas Cassou4, Marie-Jeanne Rizcallah2, Pascal Hutin2, Lenaïg Le Clech2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34003325     DOI: 10.1007/s00277-021-04557-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

1.  High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.

Authors:  Sigbjørn Berentsen; Ulla Randen; Anne Marita Vågan; Henrik Hjorth-Hansen; Anders Vik; Jakob Dalgaard; Eva-Marie Jacobsen; Aud S Thoresen; Klaus Beiske; Geir E Tjønnfjord
Journal:  Blood       Date:  2010-07-15       Impact factor: 22.113

2.  Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.

Authors:  Alexander Röth; Andreas Hüttmann; Russell P Rother; Ulrich Dührsen; Thomas Philipp
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

Review 3.  Cold agglutinin disease.

Authors:  Paul L Swiecicki; Livia T Hegerova; Morie A Gertz
Journal:  Blood       Date:  2013-06-11       Impact factor: 22.113

4.  Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Authors:  Fiorella Schischlik; Roland Jäger; Felix Rosebrock; Eva Hug; Michael Schuster; Raimund Holly; Elisabeth Fuchs; Jelena D Milosevic Feenstra; Edith Bogner; Bettina Gisslinger; Martin Schalling; Elisa Rumi; Daniela Pietra; Gottfried Fischer; Ingrid Faé; Loan Vulliard; Jörg Menche; Torsten Haferlach; Manja Meggendorfer; Anna Stengel; Christoph Bock; Mario Cazzola; Heinz Gisslinger; Robert Kralovics
Journal:  Blood       Date:  2019-05-07       Impact factor: 22.113

Review 5.  How I manage patients with cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Br J Haematol       Date:  2018-01-24       Impact factor: 6.998

6.  Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.

Authors:  Sigbjørn Berentsen; Ulla Randen; Markku Oksman; Henrik Birgens; Tor Henrik Anderson Tvedt; Jakob Dalgaard; Eivind Galteland; Einar Haukås; Robert Brudevold; Jon Hjalmar Sørbø; Inger Anne Næss; Agnieszka Malecka; Geir E Tjønnfjord
Journal:  Blood       Date:  2017-05-22       Impact factor: 22.113

7.  Sutimlimab in Cold Agglutinin Disease.

Authors:  Alexander Röth; Wilma Barcellini; Shirley D'Sa; Yoshitaka Miyakawa; Catherine M Broome; Marc Michel; David J Kuter; Bernd Jilma; Tor H A Tvedt; Joachim Fruebis; Xiaoyu Jiang; Stella Lin; Caroline Reuter; Jaime Morales-Arias; William Hobbs; Sigbjørn Berentsen
Journal:  N Engl J Med       Date:  2021-04-08       Impact factor: 91.245

8.  Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.

Authors:  Alexander Röth; Martin Bommer; Andreas Hüttmann; Dörte Herich-Terhürne; Nils Kuklik; Jan Rekowski; Veronika Lenz; Hubert Schrezenmeier; Ulrich Dührsen
Journal:  Blood Adv       Date:  2018-10-09
  8 in total
  1 in total

Review 1.  Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.

Authors:  Morie A Gertz
Journal:  Hematol Oncol Clin North Am       Date:  2022-03-11       Impact factor: 2.861

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.